Core Insights - MSC Income Fund, Inc. reported a net investment income of $16.8 million, or $0.38 per share, for the first quarter of 2025, reflecting a 15% increase from the previous year [4][7][8] - The Fund's net asset value as of March 31, 2025, was $718.9 million, or $15.35 per share, showing a slight decrease from the previous quarter [8][28] - The Fund declared a total dividend of $0.36 per share for the first quarter, which includes a regular quarterly dividend of $0.35 and a supplemental dividend of $0.01 [8] Financial Performance - Total investment income for the first quarter of 2025 was $33.2 million, a decrease of 2% from $33.9 million in the same period of 2024 [4][8] - Interest income decreased by 6% to $27.4 million, while dividend income increased by 108% to $5.1 million [4][8] - Total expenses decreased by 15.3% to $16.4 million, primarily due to a reduction in incentive fees and interest expenses [5][8] Operational Highlights - The Fund achieved a return on equity of just under 10% for the quarter [3] - The net increase in net assets resulting from operations was $15.9 million, a 50% increase compared to the first quarter of 2024 [8][10] - The Fund's liquidity as of March 31, 2025, was $163.5 million, including $39.5 million in cash and cash equivalents [12] Investment Portfolio - As of March 31, 2025, the Fund's private loan portfolio had a fair value of $767.8 million, while the lower middle market (LMM) portfolio was valued at $439.7 million [15][18] - The Fund's investment portfolio consisted of approximately 61% private loans, 35% LMM, and 2% middle market investments [18] - The weighted-average annual effective yield for the private loan portfolio was 11.6%, while for the LMM portfolio, it was 13.1% [15][16] Capital Structure - The Fund completed a follow-on equity offering in January 2025, generating net proceeds of $90.5 million, enhancing its liquidity and leverage capacity [13][14] - The Fund's debt-to-equity ratio was 0.79x as of March 31, 2025, reflecting a decline from target leverage levels due to the equity offering [17][18] - The Fund's credit facilities included a Corporate Facility with total commitments of $245 million and a SPV Facility with total commitments of $300 million [17]

Core Insights - Coherus BioSciences has completed its strategic transformation to focus on innovative oncology, with significant advancements in its product pipeline and financial performance [1][3][24] Recent Business Highlights - The company reported positive Phase 1b data for CHS-114, an anti-CCR8 antibody, at the 2025 AACR Annual Meeting, indicating potential for treating various solid tumors [1][3] - LOQTORZI, a next-generation PD-1 inhibitor, generated net revenues of $7.3 million in Q1 2025, with patient demand increasing over 15% compared to Q4 2024 [5][11] - The divestiture of UDENYCA was completed in April 2025, allowing the company to concentrate on its oncology portfolio [3][10] Financial Performance - Net revenue from continuing operations for Q1 2025 was $7.6 million, up from $2.3 million in Q1 2024, primarily driven by higher LOQTORZI sales [11] - The company reported a net loss from continuing operations of $47.4 million, or $(0.41) per share, compared to a loss of $68.0 million, or $(0.60) per share, in the same period last year [17][18] - Cash and cash equivalents decreased to $82.4 million as of March 31, 2025, down from $126.0 million at the end of 2024 [20] Pipeline Development - Ongoing studies for CHS-114 include Phase 1b trials in second-line gastric cancer and head and neck squamous cell carcinoma (HNSCC), with data readouts expected in 2026 [1][13] - Enrollment is ongoing in a Phase 2 trial of casdozokitug in combination with toripalimab and bevacizumab for first-line hepatocellular carcinoma (HCC), with initial data expected in the first half of 2026 [1][13] Strategic Focus - The company aims to maximize LOQTORZI revenues and advance its immuno-oncology candidates, including CHS-114 and casdozokitug, through strategic partnerships and label expansions [3][6][24] - Coherus is positioned to leverage its innovative oncology pipeline to enhance treatment options for cancer patients and drive future growth [3][25]

Core Insights - Atea Pharmaceuticals is advancing its Phase 3 clinical trials for the combination regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV), with ongoing patient enrollment in the C-BEYOND trial in the US and Canada, and plans to initiate the C-FORWARD trial globally [4][11][12] - The company reported promising Phase 2 results, indicating a high sustained virologic response (SVR12) rate of 98% among treatment-adherent patients and 95% overall, showcasing the regimen's potential as a best-in-class treatment for HCV [7][11] - Atea's financial results for Q1 2025 show a decrease in research and development expenses to $29.6 million, down from $57.6 million in Q1 2024, attributed to the completion of a previous COVID-19 trial and a focus on HCV development [16][20] Company Updates - Atea is hosting a virtual key opinion leader (KOL) investor event on May 14, 2025, to discuss HCV treatment challenges and the potential of its drug regimen, replacing the traditional earnings call for Q1 2025 [5][6] - The company has engaged Evercore to explore strategic alternatives to enhance shareholder value, including potential partnerships or acquisitions, while also reducing its workforce by approximately 25% to save around $15 million through 2027 [14][15] Financial Performance - As of March 31, 2025, Atea reported cash, cash equivalents, and marketable securities totaling $425.4 million, a decrease from $454.7 million at the end of 2024 [15][22] - The net loss for Q1 2025 was $34.3 million, compared to a net loss of $63.2 million in Q1 2024, reflecting improved operational efficiency [20][22] Clinical Development - The Phase 3 program includes two trials, C-BEYOND and C-FORWARD, each aiming to enroll approximately 880 treatment-naïve patients, comparing the BEM/RZR regimen to the standard sofosbuvir and velpatasvir regimen [11][12] - The primary endpoint for both trials is achieving HCV RNA levels below the lower limit of quantitation at 24 weeks, ensuring consistent evaluation across patient groups [12][13]

SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue ...

Core Viewpoint - Runway Growth Finance Corp. reported its financial results for the first quarter of 2025, highlighting a decrease in total and net investment income compared to the previous year, while maintaining a strong investment portfolio and liquidity position [2][5][12]. Financial Performance - Total investment income for Q1 2025 was $35.4 million, down from $40.0 million in Q1 2024 [5]. - Net investment income for Q1 2025 was $15.6 million, or $0.42 per share, compared to $18.7 million, or $0.46 per share, in Q1 2024 [5][8]. - The dollar-weighted annualized yield on average debt investments was 15.4% for the quarter [6]. Operating Expenses and Gains - Total operating expenses for Q1 2025 were $19.8 million, a decrease from $21.3 million in Q1 2024 [7]. - The company realized a net gain on investments of $6.1 million for Q1 2025, compared to no net realized gains or losses in Q1 2024 [7][8]. Investment Portfolio - As of March 31, 2025, the investment portfolio had a fair value of $1.0 billion, consisting of $946.4 million in term loans, with 97.9% being senior secured loans [10]. - The company completed three investments in existing portfolio companies during Q1 2025, totaling $50.7 million in funded investments [8][11]. Net Asset Value - The net asset value as of March 31, 2025, was $503.3 million, or $13.48 per share, down from $529.5 million, or $13.36 per share, as of March 31, 2024 [12]. Liquidity and Capital Resources - The company had approximately $315.4 million in available liquidity as of March 31, 2025, including $18.4 million in cash and $297.0 million in borrowing capacity [14]. - The core leverage ratio was approximately 99%, compared to 108% at the end of 2024 [14]. Distributions - The board declared a regular quarterly distribution of $0.33 per share and a supplemental distribution of $0.02 per share for Q2 2025 [15]. Recent Developments - The company entered into a Master Note Purchase Agreement on April 7, 2025, issuing $107.0 million in Series 2025A Senior Notes with a fixed interest rate of 7.51% [18][19]. - A new share repurchase program was approved, allowing the company to repurchase up to $25.0 million of its outstanding common stock [23].

BERKELEY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Recent Financial Highlights Total revenues for the three months ended March 31, 2025 were $1.5 millionTotal operating expenses for the three months ended March 31, 2025 were $22.1 millionOperating loss for the three months ended March ...

– Q1 Total Revenue up 6% YoY to $117.8 Million –– Q1 Net Income up Materially YoY to $10.0 Million or $0.23 Earnings per Share –– Q1 Operating Cash Flow up ~2x YoY to $38.4 Million –– Q1 Adjusted EBITDA up ~3x YoY to $19.3 Million – TERRE HAUTE, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”) today reported its financial results for the first quarter ended March 31, 2025. “We are pleased with our first quarter performance as we returned to top line ...

Core Insights - Mineralys Therapeutics announced positive topline results from pivotal trials Launch-HTN and Advance-HTN, demonstrating the efficacy and safety of lorundrostat for treating uncontrolled or resistant hypertension [2][3] - The company anticipates topline data from the Explore-CKD Phase 2 trial in Q2 2025 and has initiated the Explore-OSA Phase 2 trial in Q1 2025 [1][12] - The company reported a net loss of $42.2 million for Q1 2025, an increase from $31.5 million in Q1 2024, primarily due to rising research and development expenses [8][22] Clinical Trials and Results - The Launch-HTN trial achieved a 16.9 mmHg reduction in systolic blood pressure at the 50 mg dose, with a placebo-adjusted reduction of 9.1 mmHg, and sustained benefits through week 12 [3] - The Advance-HTN trial reported a 15.4 mmHg absolute reduction in systolic blood pressure at the 50 mg dose, with a placebo-adjusted reduction of 7.9 mmHg [3] - Both trials demonstrated a favorable safety profile, with low incidences of hyperkalemia at 1.1% and 1.5% for the 50 mg and 50 to 100 mg arms in the Launch-HTN trial, respectively [3] Financial Performance - As of March 31, 2025, the company had cash, cash equivalents, and investments totaling $343.0 million, up from $198.2 million at the end of 2024 [5][24] - Research and development expenses for Q1 2025 were $37.9 million, compared to $30.8 million in Q1 2024, driven by increased clinical costs and compensation expenses [6][22] - General and administrative expenses rose to $6.6 million in Q1 2025 from $4.6 million in Q1 2024, attributed to higher compensation and professional fees [7][22] Corporate Developments - Eric Warren has been appointed as Chief Commercial Officer, bringing extensive experience in cardiovascular disease to support the company's commercial strategy [2][12] - The company completed a public equity financing on March 18, 2025, raising approximately $201.2 million to strengthen its balance sheet [12] Upcoming Milestones - The Explore-CKD Phase 2 trial is expected to deliver topline data in Q2 2025, focusing on the safety and efficacy of lorundrostat in patients with chronic kidney disease [1][12] - The Explore-OSA Phase 2 trial has been initiated to evaluate lorundrostat in overweight and obese subjects with moderate-to-severe obstructive sleep apnea and hypertension [1][12]

Core Insights - Karyopharm Therapeutics reported positive developments in its Phase 3 SENTRY trial for selinexor in JAKi-naïve myelofibrosis, which has passed a planned futility analysis and is approximately 80% enrolled [2][4] - The company experienced a 5% increase in demand for XPOVIO® (selinexor) in Q1 2025 compared to Q1 2024, with total revenue of $30.0 million [5][15] - Karyopharm reaffirmed its full-year 2025 revenue guidance of $140 million to $155 million, including U.S. net product revenue guidance of $115 million to $130 million [21] Financial Performance - Total revenue for Q1 2025 was $30.0 million, down from $33.1 million in Q1 2024 [15] - U.S. net product revenue was $21.1 million in Q1 2025, compared to $26.0 million in Q1 2024, impacted by a $5.0 million increase in product return reserves [16] - License and other revenue increased to $9.0 million in Q1 2025 from $7.1 million in Q1 2024, attributed to timing of revenue recognition from Menarini [17] Research and Development Highlights - The Phase 3 SENTRY trial is evaluating the combination of selinexor and ruxolitinib, targeting 350 patients for enrollment [4] - The Phase 2 XPORT-MF-035 trial showed promising results for selinexor monotherapy in hard-to-treat myelofibrosis patients, with 67% achieving spleen volume reduction of 25% or more [10] - Enrollment continues in the Phase 3 XPORT-EC-042 trial for selinexor as maintenance therapy in advanced endometrial cancer [6] Operational Objectives - Karyopharm aims to complete target enrollment for the Phase 3 SENTRY trial by June/July 2025 and report top-line results in late 2025/early 2026 [11] - The company is exploring alternatives to extend its cash runway, with cash and investments totaling $70.3 million as of March 31, 2025 [25][14] - R&D expenses for Q1 2025 were $34.6 million, slightly down from $35.4 million in Q1 2024, reflecting reduced personnel costs [19]

Financial Performance - The company's net investment income for Q1 2025 was $0.37 per share, down from $0.40 per share in Q4 2024, representing a decrease of 7.5% [1][6] - The net asset value (NAV) per share as of March 31, 2025, was $14.93, a slight decrease of 0.3% from $14.98 as of December 31, 2024 [1][6] - Total assets increased to $3.36 billion as of March 31, 2025, compared to $3.19 billion at the end of 2024 [5][20] Investment Activity - New investment commitments during the quarter totaled $376 million, with gross fundings (excluding revolver fundings) amounting to $357 million [6][8] - The company made investments totaling $391.9 million in portfolio companies during the quarter, compared to $152.8 million in the same period of the previous year [8] - The number of investments in new portfolio companies increased to 20 from 7 year-over-year [8] Debt and Leverage - The company's outstanding debt as of March 31, 2025, was $1.94 billion, up from $1.75 billion at the end of 2024 [5][15] - The net leverage ratio was reported at 1.31x as of March 31, 2025, indicating an increase in leverage compared to previous periods [6][15] Shareholder Returns - A dividend of $0.38 per share was declared on May 7, 2025, payable on June 26, 2025, to stockholders of record as of June 10, 2025 [2][6] - The company repurchased 476,656 shares at a weighted average price of $12.75 per share during the quarter, totaling $6.1 million [11][12] Portfolio Composition - As of March 31, 2025, 93% of the investment portfolio was in first lien secured debt, maintaining a consistent level compared to previous quarters [17][18] - The weighted average yield on the total debt portfolio was 10.5% as of March 31, 2025, slightly down from 10.8% in the previous quarter [17][18]